Vertex Pharmaceuticals (MIL:1VRTX) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1VRTX Vertex Pharmaceuticals Inc MIL:1VRTX
70 GF Score
Price €424.00
GF Value €433.07
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals FFO per Share?

FFO per Share only applies to REITs.

MIL:1VRTX
70GF Score
Vertex Pharmaceuticals Inc MIL:1VRTX
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vertex Pharmaceuticals (MIL:1VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €424.00 is trading 2.1% below its estimated GF Value™ of €433.07. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for MIL:1VRTX:

  • FFO per Share:
  • GF Value™: €433.07 vs. price of €424.00 (2.1% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the MIL:1VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
70GF Score

Get the complete analysis for MIL:1VRTX

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€424.00
Price
€433.07
GF Value